Biological medicines, or biologics, represent a significant portion of the pharmaceutical pipeline, accounting for 30% of new drug approvals and up to 50% of the industry’s pipeline. Unlike small molecules, biologics are larger and have more complexities to their pharmacokinetic and pharmacodynamic properties.
Certara’s Simcyp® Biologics platform is specifically designed to address these complexities, enabling scientists to model diverse biologics modalities such as monoclonal antibodies, protein conjugates, Fc-fusion proteins, bispecifics, and other proteins and peptides.
